title: Fibrin reaction after uveitic cataract surgery: treatment and prevention.
abstract: OBJECTIVE
  To describe the management with intracameral recombinant tissue plasminogen activator (rtPA) of severe fibrin effusion after phacoemulsification, and its prevention with sustained-release dexamethasone intravitreal implant.
  
  
  METHODS
  A 59-year-old man with chronic HLA-B27-associated uveitis underwent phacoemulsification followed by a sustained-release dexamethasone intravitreal implant.
  
  
  RESULTS
  A postoperative severe fibrin reaction was completely resolved after intracameral injection of rtPA. At the time of the phacoemulsification of the fellow eye, a dexamethasone implant was injected 5 days prior to surgery, with no fibrin formation.
  
  
  CONCLUSIONS
  Intracameral rtPA may be successfully used in the management of severe fibrin reaction. Dexamethasone intravitreal implant to control postoperative inflammation may take several days until it achieves high concentrations in the vitreous.
authors: Cleveland Clinic Cole Eye Institute, Cleveland, Ohio - USA.
authors: Breno
authors: B
authors: da Rocha Lima
authors: Francesco
authors: F
authors: Pichi
authors: Paolo
authors: P
authors: Nucci
authors: Sunil K
authors: SK
authors: Srivastava
authors: Careen Y
authors: CY
authors: Lowder
mesh_terms: D003907:Dexamethasone / Q000008:administration & dosage; D004343:Drug Implants; D005337:Fibrin / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000008:administration & dosage; D015796:HLA-B27 Antigen / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014605:Uveitis / Q000150:complications* / Q000378:metabolism
chemical_list: D004343:Drug Implants; D005343:Fibrinolytic Agents; D005938:Glucocorticoids; D015796:HLA-B27 Antigen; D003907:Dexamethasone; D005337:Fibrin; D010959:Tissue Plasminogen Activator